Patent intelligence · US
US 8148560
Vaginal tablets comprising misoprostol and methods of making and using the same
Vaginal tablets comprising misoprostol and methods of making and using the same
Patent details — US 8148560
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 3, 2012
- Expiration
- Mar 29, 2032
- Applicant
- TEVA WOMEN'S HEALTH, INC.
- Claims
- 26
- CPC classes
- A61K, A61K31/5575, A61K31/57, A61K9/0034
Quick answer
US 8148560 (Vaginal tablets comprising misoprostol and methods of making and using the same) is held by TEVA WOMEN'S HEALTH, INC.. Status: granted. Granted Apr 3, 2012. Expires Mar 29, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA WOMEN'S HEALTH, INC.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/5575, A61K31/57, A61K9/0034, A61K9/2018, A61K9/2054
More from TEVA WOMEN'S HEALTH, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 8148560?
US 8148560 (Vaginal tablets comprising misoprostol and methods of making and using the same) is held by TEVA WOMEN'S HEALTH, INC.. Status: granted. Granted Apr 3, 2012. Expires Mar 29, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8148560?
TEVA WOMEN'S HEALTH, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 8148560 expire?
Our index shows an expiration date of Mar 29, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.